source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 22d ago↗ source
- Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMedIncyte presented phase 1 data at the European Society for Medical Oncology congress in Madrid, highlighting its KRAS G12D inhibitor INCB161734 combined with chemotherapy for pancreatic ductal adeno…